Therapeutic targets and new directions for antibodies developed for ovarian cancer.

MAbs · 2016 · PMC5098446 · PMID 27494775

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Furthermore, patients given catumaxomab suffered fewer symptoms from ascites and had a positive trend in OS. 85 Catumaxomab has EMA and NICE approval for use in EpCAM-positive ascites treatment (see Table 2 ). chMOv18 IgG chMOv18 IgG is a human chimeric IgG1 antibody specific for FRα, cloned from a murine MOv18 IgG antibody that was generated by immunization of mice with a surgical specimen of ovar

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.